Assessing the Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers - An Open Label, Phase I Study
Latest Information Update: 16 Mar 2026
At a glance
- Drugs Benfo-oxythiamine-Benfovir (Primary)
- Indications Cancer; COVID 2019 infections
- Focus Adverse reactions
- Acronyms BOOST
- Sponsors Benfovir
Most Recent Events
- 16 Mar 2026 New trial record